ES2525670T3 - Tratamiento de tumores metastatizados - Google Patents

Tratamiento de tumores metastatizados Download PDF

Info

Publication number
ES2525670T3
ES2525670T3 ES10186757.0T ES10186757T ES2525670T3 ES 2525670 T3 ES2525670 T3 ES 2525670T3 ES 10186757 T ES10186757 T ES 10186757T ES 2525670 T3 ES2525670 T3 ES 2525670T3
Authority
ES
Spain
Prior art keywords
compound
treatment
inhibition
metastatic tumors
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10186757.0T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Lopes De Menezes
Carla Heise
Xiaohua Xin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2525670T3 publication Critical patent/ES2525670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES10186757.0T 2005-01-27 2006-01-27 Tratamiento de tumores metastatizados Active ES2525670T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US647568P 2005-01-27
US66924505P 2005-04-06 2005-04-06
US669245P 2005-04-06
US72205305P 2005-09-29 2005-09-29
US722053P 2005-09-29

Publications (1)

Publication Number Publication Date
ES2525670T3 true ES2525670T3 (es) 2014-12-29

Family

ID=36741085

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10186757.0T Active ES2525670T3 (es) 2005-01-27 2006-01-27 Tratamiento de tumores metastatizados
ES06733986T Active ES2374570T3 (es) 2005-01-27 2006-01-27 Tratamiento de tumores metastalizados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06733986T Active ES2374570T3 (es) 2005-01-27 2006-01-27 Tratamiento de tumores metastalizados.

Country Status (22)

Country Link
US (2) US20060183750A1 (enExample)
EP (2) EP1845990B1 (enExample)
JP (2) JP5371246B2 (enExample)
KR (1) KR101387985B1 (enExample)
CN (1) CN103893181A (enExample)
AT (1) ATE526025T1 (enExample)
AU (1) AU2006208012B2 (enExample)
BR (1) BRPI0607285A2 (enExample)
CA (1) CA2596084A1 (enExample)
CY (1) CY1112570T1 (enExample)
DK (1) DK1845990T3 (enExample)
ES (2) ES2525670T3 (enExample)
IL (1) IL184866A0 (enExample)
MA (1) MA29266B1 (enExample)
MX (1) MX2007009099A (enExample)
NO (1) NO20074360L (enExample)
PL (2) PL2301546T3 (enExample)
PT (2) PT2301546E (enExample)
SG (1) SG173317A1 (enExample)
SI (1) SI2301546T1 (enExample)
TN (1) TNSN07294A1 (enExample)
WO (1) WO2006081445A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
US7470709B2 (en) 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
WO2006124413A2 (en) * 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
MX2012012051A (es) * 2010-04-16 2012-11-22 Novartis Ag Compuesto organico para usarse en el tratamiento de cancer de higado.
PH12013502099A1 (en) * 2011-05-19 2017-10-25 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
JP6990228B2 (ja) * 2016-07-14 2022-01-13 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換の化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
KR20000022040A (ko) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
GEP20053530B (en) * 1999-10-19 2005-05-25 Merck & Co Inc Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
CA2400923A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE448226T1 (de) * 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
KR100732206B1 (ko) * 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US7470709B2 (en) * 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
CN1960731B (zh) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
MX2007014612A (es) * 2005-05-18 2008-01-17 M & G Polimeri Italia Spa Composicion de poliester.
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
MA29266B1 (fr) 2008-02-01
EP2301546A1 (en) 2011-03-30
SG173317A1 (en) 2011-08-29
US20060183750A1 (en) 2006-08-17
JP5371246B2 (ja) 2013-12-18
AU2006208012B2 (en) 2011-08-04
EP1845990A4 (en) 2008-04-30
EP1845990A2 (en) 2007-10-24
CA2596084A1 (en) 2006-08-03
JP2008528617A (ja) 2008-07-31
IL184866A0 (en) 2007-12-03
AU2006208012A1 (en) 2006-08-03
WO2006081445A2 (en) 2006-08-03
EP1845990B1 (en) 2011-09-28
CN103893181A (zh) 2014-07-02
CY1112570T1 (el) 2016-02-10
HK1155664A1 (en) 2012-05-25
MX2007009099A (es) 2007-09-13
ES2374570T3 (es) 2012-02-17
EP2301546B1 (en) 2014-09-10
DK1845990T3 (da) 2012-01-02
KR101387985B1 (ko) 2014-04-25
WO2006081445A3 (en) 2007-01-11
PT1845990E (pt) 2011-12-23
SI2301546T1 (sl) 2015-01-30
JP2013177464A (ja) 2013-09-09
NO20074360L (no) 2007-10-25
US20100173873A1 (en) 2010-07-08
BRPI0607285A2 (pt) 2009-08-25
PL1845990T3 (pl) 2012-02-29
KR20070118596A (ko) 2007-12-17
PT2301546E (pt) 2014-12-18
PL2301546T3 (pl) 2015-03-31
TNSN07294A1 (en) 2008-12-31
ATE526025T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
ES2525670T3 (es) Tratamiento de tumores metastatizados
JP7274450B2 (ja) 癌を処置するための医薬組合せ
KR102678021B1 (ko) Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
JP2016523974A5 (enExample)
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2894830T3 (es) Productos combinados con inhibidores de tirosina·cinasa y su uso
JP2016530283A5 (enExample)
ES2271649T3 (es) Compuesto antitumoral y usos terapeuticos del mismo.
MY206578A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
JP2006503919A5 (enExample)
FI3439663T3 (fi) Menetelmiä lasten syöpien hoitamiseksi
JP6599444B2 (ja) サリノマイシンの窒素含有類似体、合成並びにがん幹細胞及びマラリアに対する使用
JP2003522163A5 (enExample)
MX2021001096A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
JP2019510827A5 (enExample)
ES2824774T3 (es) Nuevos derivados de quinazolinona que inhiben PI3K y composición farmacéutica que los contiene
ES2945865T3 (es) Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina
JP2008514577A5 (enExample)
Sundstrom et al. Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity
US20160229857A1 (en) Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
CN101484443A (zh) 放射线治疗增强剂
CA2602199A1 (en) Heteroaryl urea derivatives useful for inhibiting chk1
FI3405197T3 (fi) Kroonisen käsi-ihottuman hoito